Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases through the manipulation of gene regulation
The company leverages its proprietary technology platform to identify and develop small molecules that target specific genes and cellular pathways, aiming to disrupt the disease process at the molecular level. Syros is dedicated to advancing its pipeline of product candidates, which are designed to selectively modulate gene expression and provide new treatment options for patients with unmet medical needs. Through its research and development efforts, Syros aims to improve patient outcomes and ultimately transform the landscape of disease management.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Syros Pharmaceuticals, Inc. (NASDAQSYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspend the Company’s reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").
